Postprandial Glycemia and Cardiovascular Risk in Type 2 Diabetes

Postprandial glycaemia, or the rise in blood glucose following meal ingestion, has emerged as a pivotal determinant of cardiovascular risk in individuals with type 2 diabetes. Unlike fasting hyperglycaemia, which reflects basal hepatic glucose output, postprandial excursions capture the dynamic interplay of nutrient absorption, pancreatic insulin secretion, peripheral insulin sensitivity and incretin responses. Heightened postprandial peaks induce oxidative stress, endothelial dysfunction and low-grade inflammation, fostering atherogenesis and microvascular damage. Epidemiological evidence indicates that these glucose excursions contribute independently to coronary artery disease, stroke and heart failure, even when average glycaemic control assessed by haemoglobin A1c is within target. Interventions targeting postprandial dysglycaemia—encompassing dietary strategies, pharmacotherapy and advanced monitoring technologies—have demonstrated potential to attenuate these peaks and reduce cardiovascular events. As type 2 diabetes prevalence rises globally, addressing postprandial glycaemia has become central to comprehensive risk management and patient-centred care.

Research from Nature Portfolio

Recent studies have underscored the prognostic importance of non-fasting plasma glucose measurements taken several hours after meals in predicting cardiovascular mortality, independently of conventional markers of long-term glycaemic control. Late non-fasting glucose levels above defined thresholds correlate with higher risk of fatal cardiovascular events, suggesting that extended monitoring windows may improve risk stratification. In parallel, real-world trials employing Bluetooth-enabled blood-glucose metres linked to popular digital health applications have shown significant reductions in overall glycaemia, including postprandial excursions. Participants selecting from diverse mobile therapeutic platforms achieved clinically meaningful falls in haemoglobin A1c within three months, illustrating the promise of scalable digital interventions to optimise postprandial control and potentially lower cardiovascular risk in type 2 diabetes.

Postprandial Glycemia and Cardiovascular Risk in Type 2 Diabetes publication trend

The graph below shows the total number of articles in postprandial glycemia and cardiovascular risk in type 2 diabetes across all publications each year (not limited to Nature Index journals).

Technical terms

Postprandial glycaemia: The elevation in blood glucose concentration that occurs after ingestion of a meal, reflecting the body’s ability to regulate glucose in the post-absorptive state.

Haemoglobin A1c (HbA1c): A measure of the proportion of glycated haemoglobin in the blood, indicating average plasma glucose levels over the preceding two to three months.

Glycaemic excursion: The fluctuation in blood glucose levels above and below baseline during and after a meal, which can contribute to oxidative stress and vascular damage.

Continuous glucose monitoring (CGM): A technology that measures interstitial glucose concentrations in real time, enabling detailed assessment of glycaemic patterns and postprandial peaks.

References

1. Improved glycemic outcomes in people with type 2 diabetes using smart blood glucose monitoring integrated with popular digital health therapeutics. Scientific Reports (2025).
2. Postprandial Plasma Glucose between 4 and 7.9 h May Be a Potential Diagnostic Marker for Diabetes. Biomedicines (2024).
3. An Innovative, Paradigm-Shifting Lifestyle Intervention to Reduce Glucose Excursions With the Use of Continuous Glucose Monitoring to Educate, Motivate, and Activate Adults With Newly Diagnosed Type 2 Diabetes: Pilot Feasibility Study. JMIR Diabetes (2022).
4. Acute and long-term effects of saxagliptin on post-prandial glycemic response in obese patients with impaired glucose tolerance. Nutrition Metabolism and Cardiovascular Diseases (2020).
5. Late non-fasting plasma glucose predicts cardiovascular mortality independent of hemoglobin A1c. Scientific Reports (2022).